GINDRAUX, Florelle, Nicola HOFMANN, Marta AGUDO-BARRIUSO, Mariastefania ANTICA, Pedro Silva COUTO, Marie DUBUS, Serhiy FOROSTYAK, Lenart GIRANDON, Roberto GRAMIGNOLI, Marcin JURGA, Sergio LIARTE, Ruta NAVAKAUSKIENE, Volodymyr SHABLII, Xavier LAFARGE and Francisco J NICOLAS. Perinatal derivatives application: Identifying possibilities for clinical use. Frontiers in bioengineering and biotechnology. Laussane: Frontiers Media S.A., 2022, vol. 10, October 2022, p. 1-20. ISSN 2296-4185. Available from: https://dx.doi.org/10.3389/fbioe.2022.977590.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Perinatal derivatives application: Identifying possibilities for clinical use
Authors GINDRAUX, Florelle (guarantor), Nicola HOFMANN, Marta AGUDO-BARRIUSO, Mariastefania ANTICA, Pedro Silva COUTO, Marie DUBUS, Serhiy FOROSTYAK (203 Czech Republic, belonging to the institution), Lenart GIRANDON, Roberto GRAMIGNOLI, Marcin JURGA, Sergio LIARTE, Ruta NAVAKAUSKIENE, Volodymyr SHABLII, Xavier LAFARGE and Francisco J NICOLAS.
Edition Frontiers in bioengineering and biotechnology, Laussane, Frontiers Media S.A. 2022, 2296-4185.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10601 Cell biology
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.700
RIV identification code RIV/00216224:14110/22:00128445
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3389/fbioe.2022.977590
UT WoS 000876508500001
Keywords in English clinical trials; perinatal derivatives; ICD-10=international classification of diseases; questionnaire for PnD use in human conditions; amniotic membrane
Tags 14110229, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 31/1/2023 13:22.
Abstract
Perinatal derivatives are drawing growing interest among the scientific community as an unrestricted source of multipotent stromal cells, stem cells, cellular soluble mediators, and biological matrices. They are useful for the treatment of diseases that currently have limited or no effective therapeutic options by means of developing regenerative approaches. In this paper, to generate a complete view of the state of the art, a comprehensive 10-years compilation of clinical-trial data with the common denominator of PnD usage has been discussed, including commercialized products. A set of criteria was delineated to challenge the 10-years compilation of clinical trials data. We focused our attention on several aspects including, but not limited to, treated disorders, minimal or substantial manipulation, route of administration, dosage, and frequency of application. Interestingly, a clear correlation of PnD products was observed within conditions, way of administration or dosage, suggesting there is a consolidated clinical practice approach for the use of PnD in medicine. No regulatory aspects could be read from the database since this information is not mandatory for registration. The database will be publicly available for consultation. In summary, the main aims of this position paper are to show possibilities for clinical application of PnD and propose an approach for clinical trial preparation and registration in a uniform and standardized way. For this purpose, a questionnaire was created compiling different sections that are relevant when starting a new clinical trial using PnD. More importantly, we want to bring the attention of the medical community to the perinatal products as a consolidated and efficient alternative for their use as a new standard of care in the clinical practice.
PrintDisplayed: 12/5/2024 15:13